Cargando…
Metabolic plasticity imparts erlotinib-resistance in pancreatic cancer by upregulating glucose-6-phosphate dehydrogenase
Pancreatic ductal adenocarcinoma (PDAC) is one of the most malignant forms of cancer. Lack of effective treatment options and drug resistance contributes to the low survival among PDAC patients. In this study, we investigated the metabolic alterations in pancreatic cancer cells that do not respond t...
Autores principales: | Sharma, Neha, Bhushan, Alok, He, Jun, Kaushal, Gagan, Bhardwaj, Vikas |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7507640/ https://www.ncbi.nlm.nih.gov/pubmed/32974013 http://dx.doi.org/10.1186/s40170-020-00226-5 |
Ejemplares similares
-
Role of Intensive Training in Strengthening the Skills of HIV Counselors for Imparting Quality ICTC Services
por: Dhadwal, D, et al.
Publicado: (2009) -
Glucose-6-phosphate dehydrogenase deficiency and hydroxychloroquine in the COVID-19 era: a mini review
por: Onori, Maria Elisabetta, et al.
Publicado: (2021) -
Glucose-6-phosphate Dehydrogenase (G6PD) A-Variant Frequency and Novel Polymorphism in Haiti
por: Vincent, Jeanne P, et al.
Publicado: (2022) -
Retinitis Pigmentosa Associated with Glucose-6-Phosphate Dehydrogenase Deficiency
por: Thiel, Bryan, et al.
Publicado: (2017) -
Propofol infusion in an infant with glucose-6-phosphate dehydrogenase deficiency
por: Sharma, Vandana, et al.
Publicado: (2018)